Carboplatin AUC-10

Phase 2Small molecule

BBarts & The London NHS Trust

Carboplatin AUC-10 is one of 5 small molecule programs targeting Seminoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SeminomaActive, not recruiting

SeminomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Seminoma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

4 2

Jevtana

Sanofi

Phase 2

1 3

Vepesid

AAvyxa

Phase 2

2 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 5

Carboplatin AUC-10

BBarts & The London NHS Trust

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seminoma1 trial

Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma

Completed·BBarts & The London NHS Trust·Phase 2·NCT02272816·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carboplatin AUC-10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin AUC-10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin AUC-10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Barts & The London NHS Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBarts & The London NHS Trust

Carboplatin AUC-10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seminoma1 trial

References

Drug Info

Quick Facts

Related News